Streetwise
Lauren Rudd
Sunday, September 25, 2011
Oh, To Have a Crystal Ball Again
“Persons pretending to forecast the future shall be
considered disorderly under subdivision 3, section 901 of the criminal code and
liable to a fine of $250 and/or six months in prison.”
Section 889, New York State Code of Criminal
Procedure
A year ago I wrote that Wall Street was a terrifying place.
Unfortunately, little has changed. Moreover, the same question is continually
being asked of all who will listen, “This market is frightening; do you have any
advice,” which enables one group to thrive and prosper...the psychics.
Oh, to be a soothsayer of such repute so as to know all the
answers. Unfortunately, with the passing of Madame Marie, who is memorialized in
the words of Bruce Springsteen’s song, “4th of July, Asbury Park (Sandy)” and
who was actually arrested at one time under the above statute, I am completely
out of crystal balls.
Nonetheless, there are countless prognosticators willing to
offer up unsolicited opinions for a “small” cash payment on your part. They run
the gamut from the biased and mundane to such nonsensical advice as, “sell
everything and buy gold.” The result is a deafening din of ridiculous discourse.
Unfortunately, all the rhetoric in the world is not going to
help your portfolio. What you need is a modicum of cool rationality, combined
with a measure of forward thinking. Yet, if you are like many investors you feel
that over the past several years Wall Street has shredded your life, your
livelihood and burdened future generations with a crushing debt. Actually, it
probably has but that requires a considerably longer dialogue than I have space
for here.
Not to downplay the gravity of the current situation, but the
ongoing economic recovery is analogous to that of a locomotive. Its initial
motion is nearly indiscernible. But then it begins to slowly pick up speed, its
wheels sometimes aided by sand to prevent slippage (analogous to stimulus
programs). And in short order it gains traction and finally reaches undaunted
speed despite pulling a mammoth load, in this case the national debt.
Meanwhile, you still have to deal with the current investment
environment. You might begin by ignoring the perturbations on Wall Street while
acknowledging that quality investment opportunities remain plentiful. One
example is Varian Medical Systems (VAR), a company that manufacturers cancer
therapy systems.
When I last talked about the company a year ago, my earnings
estimate for the 2010 fiscal year ended September 30 was $2.93 per share with a
12-month price target on the shares of $69, as compared to a price back then of
$59. The earnings number worked out fine with the Varian reporting $2.96 per
share for the year. And the share price was rising steadily until last July at
which time the shares were trading at about $69. Then Wall Street sort of fell
apart and the shares recently closed at $50.96.
So how did Varian’s fundamentals perform? For the third
quarter ending June 30, revenues increased 12 percent to $649 million. Net
earnings for the quarter were $0.83 per share, up 12 percent from a year-ago.
Total backlog increased by 10 percent to $2.3 billion and the company ended the
quarter with $568 million in cash, debt of $18 million and shareholder equity of
$1.5 billion.
Operating expenses were about even with the year-ago period
at 21 percent of revenue. Third quarter operating earnings were up 7 percent to
$140 million, or 22 percent of revenue. On a year-to-date basis, operating
earnings were up 11 percent to 23 percent of revenue. Corporate guidance for the
year is 10 percent revenue growth and earnings per share of between $3.42 and
$3.45.
The intrinsic value of the shares, using a discounted
earnings model with an earnings growth rate of 14.33 percent applied to earnings
of $ 360.4 million and a discount rate of 15 percent yields an intrinsic value
of $81 per share. The more conservative free cash flow to the firm model yields
an intrinsic value of $111 per share. As previously mentioned, the shares
recently closed at $50.96.
My earnings estimate for fiscal 2011 is $3.48 per share, with a 12-month target
price on the stock of $61, for an annualized capital gain of 15 percent.